Yunnan Walvax Biotechnology Co., Ltd. announced that its subsidiary received the Phase III clinical trial report for the 13-valent pneumococcal polysaccharide conjugate vaccine's 2p+1 immunization schedule in Indonesia. The trial met its objectives, supporting the vaccine's registration and market competitiveness. This milestone is expected to positively impact overseas sales.
Summary generated by AI · Always verify with source document
Stock Code: 300142 Stock Abbreviation: Walvax Biotechnology Announcement No.: 2026-053
Yunnan Walvax Biotechnology Co., Ltd.
Announcement on the Phase III Clinical Trial Report for the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine's 2p+1 Immunization Schedule in Indonesia
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, without any false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.